Perfil lipídico de atazanavir
Lipid profile of atazanavir
Esteban Martínez Chamorro
Autor para correspondencia
esteban@fundsoriano.es
Correspondencia: Dr. E. Martínez. Servicio de Infecciones. Hospital Clínic. Villarroel, 170. 08036 Barcelona. España.
Correspondencia: Dr. E. Martínez. Servicio de Infecciones. Hospital Clínic. Villarroel, 170. 08036 Barcelona. España.
Servicio de Infecciones. Hospital Clínic-Institut d’Investigaciones Biomèdiques August Pi i Sunyer. Universidad de Barcelona. España
Leído
2373
Vecesse ha leído el artículo
942
Total PDF
1431
Total HTML
Compartir estadísticas
array:23 [ "pii" => "S0213005X08766187" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(08)76618-7" "estado" => "S300" "fechaPublicacion" => "2008-12-01" "aid" => "76618" "copyright" => "Elsevier España S.L.. Todos los derechos reservados" "copyrightAnyo" => "2008" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2008;26 Supl 17:34-40" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1590 "formatos" => array:3 [ "EPUB" => 12 "HTML" => 1003 "PDF" => 575 ] ] "itemSiguiente" => array:18 [ "pii" => "S0213005X08766199" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(08)76619-9" "estado" => "S300" "fechaPublicacion" => "2008-12-01" "aid" => "76619" "copyright" => "Elsevier España S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2008;26 Supl 17:41-4" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 4319 "formatos" => array:3 [ "EPUB" => 17 "HTML" => 1840 "PDF" => 2462 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Efectos adversos de atazanavir" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "41" "paginaFinal" => "44" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Adverse effects of atazanavir" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. Palacios, M. González, J. Ruiz, Jesús Santos" "autores" => array:4 [ 0 => array:2 [ "nombre" => "R." "apellidos" => "Palacios" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "González" ] 2 => array:2 [ "nombre" => "J." "apellidos" => "Ruiz" ] 3 => array:2 [ "nombre" => "Jesús" "apellidos" => "Santos" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X08766199?idApp=UINPBA00004N" "url" => "/0213005X/0000002600000S17/v1_201305090109/S0213005X08766199/v1_201305090109/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0213005X08766175" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(08)76617-5" "estado" => "S300" "fechaPublicacion" => "2008-12-01" "aid" => "76617" "copyright" => "Elsevier España S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2008;26 Supl 17:28-33" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 3492 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 2473 "PDF" => 1011 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Resistencia viral y barrera genética de atazanavir" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "28" "paginaFinal" => "33" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Viral resistance and genetic barrier of atazanavir" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Carmen De Mendoza, Carolina Garrido, Ana Treviño, Lourdes Anta, Eva Poveda, Vicente Soriano" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Carmen De" "apellidos" => "Mendoza" ] 1 => array:2 [ "nombre" => "Carolina" "apellidos" => "Garrido" ] 2 => array:2 [ "nombre" => "Ana" "apellidos" => "Treviño" ] 3 => array:2 [ "nombre" => "Lourdes" "apellidos" => "Anta" ] 4 => array:2 [ "nombre" => "Eva" "apellidos" => "Poveda" ] 5 => array:2 [ "nombre" => "Vicente" "apellidos" => "Soriano" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X08766175?idApp=UINPBA00004N" "url" => "/0213005X/0000002600000S17/v1_201305090109/S0213005X08766175/v1_201305090109/es/main.assets" ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Perfil lipídico de atazanavir" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "34" "paginaFinal" => "40" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Esteban Martínez Chamorro" "autores" => array:1 [ 0 => array:4 [ "nombre" => "Esteban Martínez" "apellidos" => "Chamorro" "email" => array:1 [ 0 => "esteban@fundsoriano.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor1" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Servicio de Infecciones. Hospital Clínic-Institut d’Investigaciones Biomèdiques August Pi i Sunyer. Universidad de Barcelona. España" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "⁎" "correspondencia" => "Correspondencia: Dr. E. Martínez. Servicio de Infecciones. Hospital Clínic. Villarroel, 170. 08036 Barcelona. España." ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Lipid profile of atazanavir" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec137565" "palabras" => array:3 [ 0 => "Atazanavir" 1 => "Hiperlipidemia" 2 => "Riesgo cardiovascular" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Key words" "identificador" => "xpalclavsec137564" "palabras" => array:3 [ 0 => "Atazanavir" 1 => "Hyperlipaemia" 2 => "Cardiovascular risk" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">En la actualidad se sabe que la exposición al tratamiento antirretroviral, particularmente a los inhibidores de proteasa clásicos, se asocia con un incremento del riesgo de presentar enfermedad cardiovascular, aunque la interrupción del tratamiento antirretroviral puede ocasionar un riesgo aún mayor. Se han emitido recomendaciones sobre la intervención ante la dislipidemia y el riesgo cardiovascular en personas seropositivas. Estas recomendaciones se semejan a las de la población general, pero incluyen el carácter particular de considerar incluir un tratamiento antirretroviral benigno con los lípidos en la medida de lo posible.</p><p class="elsevierStyleSimplePara elsevierViewall">Atazanavir presenta unas características diferentes de las de otros inhibidores de la proteasa en cuanto a sus efectos sobre el tejido adiposo y el metabolismo en general. Atazanavir no se ha asociado con los aumentos de las concentraciones de colesterol total, colesterol unido a lipoproteínas de baja densidad (cLDL) o triglicéridos que han presentado otros inhibidores de la proteasa en pautas de inicio, rescate o simplificación. Los resultados de los estudios in vitro y clínicos son claros y contundentes.</p><p class="elsevierStyleSimplePara elsevierViewall">Estas características le confieren un papel singular muy atractivo a la hora de decidir el tratamiento antirretroviral más adecuado para una proporción de pacientes infectados por el virus de la inmunodeficiencia humana (VIH) en los que la reducción del riesgo cardiovascular constituya una prioridad.</p>" ] "en" => array:1 [ "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">It is currently known that exposure to antiretroviral treatment, particularly to the classic protease inhibitors, is associated with an increased risk of suffering from cardiovascular disease, although stopping antiretroviral treatment can cause an even greater risk. Recommendations have been made on how to deal with dyslipaemia and cardiovascular risk in seropositive patients. These recommendations are similar to those for the general population, but include the particular feature of considering including benign treatment with lipids wherever possible.</p><p class="elsevierStyleSimplePara elsevierViewall">Atazanavir has different characteristics from other protease inhibitors as regards its effects on adipose tissue and metabolism in general. Atazanavir is not associated with increases in total cholesterol, LDL-cholesterol or triglycerides as with other PI in initial, rescue or simplification therapy. The results of in vitro studies and clinical studies are clear and convincing. These characteristics give it a particular role that is very attractive when deciding the most suitable antiretroviral treatment for a proportion of HIV-infected patients in whom the reduction in cardiovascular risk is seen as a priority.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliografía" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:47 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "F.J.J. Palella" 1 => "K.M. Delaney" 2 => "A.C. Moorman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199803263381301" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1998" "volumen" => "338" "paginaInicial" => "853" "paginaFinal" => "860" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9516219" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "HIV chemotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "D.D. Richman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/35073673" "Revista" => array:6 [ "tituloSerie" => "Nature" "fecha" => "2001" "volumen" => "410" "paginaInicial" => "995" "paginaFinal" => "1001" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11309630" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J.Q. Purnell" 1 => "A. Zambon" 2 => "R.H. Knopp" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2000" "volumen" => "14" "paginaInicial" => "51" "paginaFinal" => "57" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10714567" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "For the Swiss HIV Cohort Study" "etal" => true "autores" => array:3 [ 0 => "D. Periard" 1 => "A. Telenti" 2 => "P. Sudre" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Circulation" "fecha" => "1999" "volumen" => "100" "paginaInicial" => "700" "paginaFinal" => "705" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10449690" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sex differences in HAART-associated dyslipidaemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "H. Pernerstorfer-Schoen" 1 => "B. Jilma" 2 => "A. Perschler" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2001" "volumen" => "15" "paginaInicial" => "725" "paginaFinal" => "734" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11371687" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A.D. Roberts" 1 => "R.A. Muesing" 2 => "D.M. Parenti" 3 => "J. Hsia" 4 => "A.G. Wasserman" 5 => "G.L. Simon" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/520231" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "1999" "volumen" => "29" "paginaInicial" => "441" "paginaFinal" => "443" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10476757" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "K. Mulligan" 1 => "C. Grunfeld" 2 => "V.W. Tai" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2000" "volumen" => "23" "paginaInicial" => "35" "paginaFinal" => "43" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10708054" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Metabolic effects of indinavir in healthy HIV-seronegative men" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M.A. Noor" 1 => "J.C. Lo" 2 => "K. Mulligan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2001" "volumen" => "15" "paginaInicial" => "F11" "paginaFinal" => "F18" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11399973" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Hsu" 1 => "G.R. Granneman" 2 => "G. Witt" 3 => "C. Locke" 4 => "J. Denissen" 5 => "A. Molla" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Antimicrob Agents Chemother" "fecha" => "1997" "volumen" => "41" "paginaInicial" => "898" "paginaFinal" => "905" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9145841" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S.D. Shafran" 1 => "L.D. Mashinter" 2 => "S.E. Roberts" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-1293.2005.00328.x" "Revista" => array:6 [ "tituloSerie" => "HIV Med" "fecha" => "2005" "volumen" => "6" "paginaInicial" => "421" "paginaFinal" => "425" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16268824" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Combination antiretroviral therapy and the risk of myocardial infarction" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa030218" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2003" "volumen" => "349" "paginaInicial" => "1993" "paginaFinal" => "2003" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14627784" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Class of antiretroviral drugs and the risk of myocardial infarction" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "The DAD Study Group" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa062744" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2007" "volumen" => "356" "paginaInicial" => "1723" "paginaFinal" => "1735" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17460226" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "DAD Study Group" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(08)60423-7" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2008" "volumen" => "371" "paginaInicial" => "1417" "paginaFinal" => "1426" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18387667" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "JAMA" "fecha" => "2001" "volumen" => "285" "paginaInicial" => "2486" "paginaFinal" => "2497" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11368702" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group" "etal" => true "autores" => array:6 [ 0 => "M.P. Dubé" 1 => "J.H. Stein" 2 => "J. Aberg" 3 => "C.J. Fichtenbaum" 4 => "J.G. Gerber" 5 => "K.T. Tashima" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/378131" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2003" "volumen" => "37" "paginaInicial" => "613" "paginaFinal" => "627" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12942391" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "The EACS Executive Committee" "etal" => false "autores" => array:6 [ 0 => "J.D. Lundgren" 1 => "M. Battegay" 2 => "G. Behrens" 3 => "S. De Wit" 4 => "G. Guaraldi" 5 => "C. Katlama" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-1293.2007.00534.x" "Revista" => array:6 [ "tituloSerie" => "HIV Med" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "72" "paginaFinal" => "81" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18257770" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C. Grunfeld" 1 => "M. Pang" 2 => "W. Doerrler" 3 => "J.K. Shigenaga" 4 => "P. Jensen" 5 => "K.R. Feingold" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1210/jcem.74.5.1373735" "Revista" => array:6 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "1992" "volumen" => "74" "paginaInicial" => "1045" "paginaFinal" => "1052" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1373735" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Van der Valk" 1 => "J.J.P. Kastelein" 2 => "R. Murphy" 3 => "F. Van Leth" 4 => "C. Katlama" 5 => "A. Horban" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2001" "volumen" => "15" "paginaInicial" => "2407" "paginaFinal" => "2414" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11740191" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "CD4+ Count-Guided Interruption of Antiretroviral Treatment" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "The Strategies for Management of Antiretroviral Therapy (SMART) Study Group" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa062360" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2006" "volumen" => "355" "paginaInicial" => "2283" "paginaFinal" => "2296" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17135583" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Phillips" 1 => "A. Carr" 2 => "J. Neuhaus" 3 => "F. Visnegarwala" 4 => "R. Prineas" 5 => "W.J. Burman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Antivir Ther" "fecha" => "2008" "volumen" => "13" "paginaInicial" => "177" "paginaFinal" => "187" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18505169" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lipids, diabetes, and coronary heart disease: insights from the Framingham Study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "W.B. Kannel" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am Heart J" "fecha" => "1985" "volumen" => "110" "paginaInicial" => "1100" "paginaFinal" => "1107" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/4061265" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Bonnet" 1 => "M. Savès" 2 => "C. Droz" 3 => "E. Peuchant" 4 => "G. Chene" 5 => "J. Beylot" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2000" "volumen" => "25" "paginaInicial" => "199" "paginaFinal" => "200" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11103052" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Plasma lipids in HIV-infected patients: a prospective study in 95 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Constans" 1 => "J.L. Pellegrin" 2 => "E. Peuchant" 3 => "M.F. Dumon" 4 => "I. Pellegrin" 5 => "C. Sergeant" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Eur J Clin Invest" "fecha" => "1994" "volumen" => "24" "paginaInicial" => "416" "paginaFinal" => "420" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7957495" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "HIV protease inhibitor-related lipodystrophy syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A. Carr" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/313854" "Revista" => array:7 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2000" "volumen" => "30" "numero" => "Suppl 2" "paginaInicial" => "S135" "paginaFinal" => "S142" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10860898" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Indinavir inhibits sterol-regulatory element- binding protein-1c- dependent lipoprotein lipase and fatty acid synthase gene activations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.R. Miserez" 1 => "P.Y. Muller" 2 => "V. Spaniol" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2002" "volumen" => "16" "paginaInicial" => "1587" "paginaFinal" => "1594" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12172079" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.S. Liang" 1 => "O. Distler" 2 => "D.A. Cooper" 3 => "H. Jamil" 4 => "R.J. Deckelbaum" 5 => "H. Ginsberg" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Nat Med" "fecha" => "2001" "volumen" => "7" "paginaInicial" => "1327" "paginaFinal" => "1331" ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Differentiation of atazanivir from other HIV-protease inhibitors in preclinical models of glucose uptake, lipogenesis, and proteasome function [abstract 10]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S. Wang" 1 => "R. Mulvey" 2 => "N. Laing" 3 => "O. Flint" 4 => "R.A. Parker" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV" "conferencia" => "San Diego, CA" "serieFecha" => "2002" ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir plus saquinavir once daily favorably affects total cholesterol (TC), fasting triglyceride (TG), and fasting LDL cholesterol (LDL) profiles in patients failing prior therapy (trial AI424-009, week 48) [abstract 42]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "D.W. Haas" 1 => "C. Zala" 2 => "S. Schrader" 3 => "A. Thiry" 4 => "R. McGovern" 5 => "S. Schnittman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "9th Conference for Retroviruses and Opportunistic Infections" "conferencia" => "Seattle, WA; February 26" "serieFecha" => "2002" ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparative results (phase II 48-week): BMS-232632, stavudine, lamivudine as HAART for treatment-naïve HIV(+) patients (AI424-008) [abstract I- 667]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "I. Sanne" 1 => "P. Cahn" 2 => "L. Percival" 3 => "P. Phanuphak" 4 => "T.GM. Kelleher" 5 => "G. Pantaleo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "41st Interscience Conference on Antimicrobial Agents and Chemotherapy" "conferencia" => "Chicago, IL; December 18" "serieFecha" => "2001" ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The mechanism of insulin resistance caused by HIV protease inhibitor therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "H. Murata" 1 => "P.W. Hruz" 2 => "M. Mueckler" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1074/jbc.C000228200" "Revista" => array:6 [ "tituloSerie" => "J Biol Chem" "fecha" => "2000" "volumen" => "275" "paginaInicial" => "20251" "paginaFinal" => "20254" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10806189" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib31" "etiqueta" => "31." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein- 1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Caron" 1 => "M. Auclair" 2 => "C. Vigouroux" 3 => "M. Glorian" 4 => "C. Forest" 5 => "J. Capeau" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Diabetes" "fecha" => "2001" "volumen" => "50" "paginaInicial" => "1378" "paginaFinal" => "1388" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11375339" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib32" "etiqueta" => "32." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Differential effects of HIV protease inhibitors on proteasome, gene expresión, and lipogenesis provide a mechanism for PI-associated dyslipidemia and atazanavir's favourable lipid profile" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.A. Parker" 1 => "S. Wang" 2 => "R. Mulvey" 3 => "C. Elosua" 4 => "W. Fenderson" 5 => "F. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:2 [ "titulo" => "11th Conference on Retroviruses and opportunistic Infections" "serieFecha" => "2004" ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib33" "etiqueta" => "33." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.G. Jemsek" 1 => "E. Arathoon" 2 => "M. Arlotti" 3 => "C. Perez" 4 => "N. Sosa" 5 => "Pokrovskiy." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/498505" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2006" "volumen" => "42" "paginaInicial" => "273" "paginaFinal" => "280" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16355341" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib34" "etiqueta" => "34." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of atazanavir, with or without ritonavir, as part of oncedaily highly active antiretroviral therapy regimens in antiretroviral-naive patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.RN. Malan" 1 => "E. Krantz" 2 => "N. David" 3 => "V. Wirtz" 4 => "J. Hammond" 5 => "D. McGrath" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAI.0b013e31815ace6a" "Revista" => array:6 [ "tituloSerie" => "J Acquir immune Defic Syndr" "fecha" => "2008" "volumen" => "47" "paginaInicial" => "161" "paginaFinal" => "167" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17971713" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib35" "etiqueta" => "35." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.Y. Smith" 1 => "W.G. Weinberg" 2 => "E. DeJesus" 3 => "M.A. Fischl" 4 => "Q. Liao" 5 => "L.L. Ross" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1742-6405-5-5" "Revista" => array:5 [ "tituloSerie" => "AIDS Res Ther" "fecha" => "2008" "volumen" => "5" "paginaInicial" => "5" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18373851" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib36" "etiqueta" => "36." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naive patients: a 48-week pilot study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Elion" 1 => "E. De Jesus" 2 => "M. Sension" 3 => "D. Berger" 4 => "W. Towner" 5 => "G. Richmond" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1310/hct0903-152" "Revista" => array:6 [ "tituloSerie" => "HIV Clin Trials" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "152" "paginaFinal" => "163" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18547902" "web" => "Medline" ] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib37" "etiqueta" => "37." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of once-daily atazanavir/ritonavir compared with twice-daily loipinavir/ritonavir, each in combination with tenofovir and emtricitabine in ARV-naive HIV-1-infected subjects: the CASTLE study, 48-week results" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.M. Molina" 1 => "J. Andrade-Villanueva" 2 => "J. Echevarria" 3 => "P. Chetchotisakd" 4 => "J. Corral" 5 => "N. David" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections" "conferencia" => "Boston Massachussets" "serieFecha" => "2008" ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib38" "etiqueta" => "38." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir: a once-daily protease inhibitor with a superior lipid profile: results of clinical trials at week 48" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.J. Piliero" 1 => "P. Cahn" 2 => "G. Pantaleo" 3 => "J. Gatell" 4 => "K. Squires" 5 => "L. Percival" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "9th Conference on Retroviruses and Opportunistic Infections" "conferencia" => "Seattle WA" "serieFecha" => "2002" ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib39" "etiqueta" => "39." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Haas" 1 => "C. Zala" 2 => "S. Schrader" 3 => "P. Piliero" 4 => "H. Jaeger" 5 => "D. Nunes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/01.aids.0000060389.18106.0a" "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2003" "volumen" => "17" "paginaInicial" => "1339" "paginaFinal" => "1349" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12799555" "web" => "Medline" ] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib40" "etiqueta" => "40." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antiviral efficacy, metabolic changes and safety of atazanavir (ATV) versus lopinavir/ritonavir (LPV/RTV) in combination with two NRTIs in patients who have experienced virological failure with prior PI-containing regimen(s): 24-week results from BMS AI424-043" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L. Nieto-Cisneros" 1 => "C. Zala" 2 => "W.J. Fessel" 3 => "J. Gonzalez-Garcia" 4 => "C. Cohen" 5 => "R. McGovern" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "Program and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment" "conferencia" => "Paris" "serieFecha" => "2003" ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib41" "etiqueta" => "41." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in combination with tenofovir (TFV) and one NRTI in patients who have experienced virologic failure to multiple HAART regimens: 16 week results from BMS AI424-045" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Badaro" 1 => "E. De Jesus" 2 => "A. Lazzarin" 3 => "J. Jemsek" 4 => "B. Clotet" 5 => "A. Rightmire" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "Program and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment" "conferencia" => "Paris" "serieFecha" => "2003" ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib42" "etiqueta" => "42." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2007)" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "Panel de expertos de GESIDA y Plan Nacional sobre el Sida" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Enferm Infecc Microbiol Clin" "fecha" => "2007" "volumen" => "25" "paginaInicial" => "32" "paginaFinal" => "53" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17261244" "web" => "Medline" ] ] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib43" "etiqueta" => "43." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic supresión switched from a stable, boosted or unboosted portease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Gatell" 1 => "D. Salmon-Ceron" 2 => "A. Lazzarin" 3 => "Van. Wijngaerden" 4 => "F. Antunes" 5 => "C. Leen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2007" "volumen" => "44" "paginaInicial" => "1484" "paginaFinal" => "1492" ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib44" "etiqueta" => "44." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virologic suppression receiving a lopinavir/ritonavir-containing HAART: the ATAZIP study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "J. Mallolas" 1 => "D. Podzamczer" 2 => "P. Domingo" 3 => "B. Clotet" 4 => "E. Ribera" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:2 [ "titulo" => "4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia" "serieFecha" => "2007" ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib45" "etiqueta" => "45." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. Soriano" 1 => "P. García-Gascó" 2 => "E. Vispo" 3 => "A. Ruiz-Sancho" 4 => "F. Blanco" 5 => "L. Martín-Carbonero" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Antimcrob Chemother" "fecha" => "2008" "volumen" => "61" "paginaInicial" => "200" "paginaFinal" => "205" ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib46" "etiqueta" => "46." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Continuation of BID boosted PI vs switch to once-daily boosted atazanavir in subjects with truncal adipositiy: 24-week interim analysis of the 96-week multicentre, open-label, randomised, prospective REAL study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Moyle" 1 => "J. Andrade" 2 => "P.M. Girard" 3 => "A. Antinori" 4 => "P. Salvato" 5 => "J.R. Bogner" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "11th European AIDS Conference" "conferencia" => "Madrid, Spain" "serieFecha" => "2007" ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib47" "etiqueta" => "47." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Colafigli" 1 => "S. Di Giambenedetto" 2 => "L. Bracciale" 3 => "E. Tamburrini" 4 => "R. Cauda" 5 => "A. De Luca" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-1293.2007.00541.x" "Revista" => array:6 [ "tituloSerie" => "HIV Medicine" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "172" "paginaFinal" => "179" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18217998" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/0213005X/0000002600000S17/v1_201305090109/S0213005X08766187/v1_201305090109/es/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/0213005X/0000002600000S17/v1_201305090109/S0213005X08766187/v1_201305090109/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X08766187?idApp=UINPBA00004N" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 1 | 0 | 1 |
| 2024 Octubre | 11 | 4 | 15 |
| 2024 Septiembre | 10 | 4 | 14 |
| 2024 Agosto | 10 | 3 | 13 |
| 2024 Julio | 19 | 3 | 22 |
| 2024 Junio | 11 | 4 | 15 |
| 2024 Mayo | 6 | 6 | 12 |
| 2024 Abril | 3 | 5 | 8 |
| 2024 Marzo | 7 | 3 | 10 |
| 2024 Febrero | 4 | 4 | 8 |
| 2024 Enero | 7 | 0 | 7 |
| 2023 Diciembre | 6 | 5 | 11 |
| 2023 Noviembre | 5 | 5 | 10 |
| 2023 Octubre | 8 | 0 | 8 |
| 2023 Septiembre | 4 | 1 | 5 |
| 2023 Agosto | 6 | 1 | 7 |
| 2023 Julio | 3 | 6 | 9 |
| 2023 Junio | 4 | 3 | 7 |
| 2023 Mayo | 3 | 2 | 5 |
| 2023 Abril | 8 | 4 | 12 |
| 2023 Marzo | 6 | 3 | 9 |
| 2023 Febrero | 4 | 1 | 5 |
| 2023 Enero | 4 | 3 | 7 |
| 2022 Diciembre | 19 | 4 | 23 |
| 2022 Noviembre | 9 | 5 | 14 |
| 2022 Octubre | 4 | 5 | 9 |
| 2022 Septiembre | 11 | 20 | 31 |
| 2022 Agosto | 7 | 4 | 11 |
| 2022 Julio | 14 | 7 | 21 |
| 2022 Junio | 10 | 5 | 15 |
| 2022 Mayo | 5 | 7 | 12 |
| 2022 Abril | 9 | 9 | 18 |
| 2022 Marzo | 9 | 9 | 18 |
| 2022 Febrero | 8 | 5 | 13 |
| 2022 Enero | 3 | 4 | 7 |
| 2021 Diciembre | 7 | 10 | 17 |
| 2021 Noviembre | 5 | 9 | 14 |
| 2021 Octubre | 5 | 8 | 13 |
| 2021 Septiembre | 5 | 6 | 11 |
| 2021 Agosto | 9 | 6 | 15 |
| 2021 Julio | 5 | 9 | 14 |
| 2021 Junio | 3 | 4 | 7 |
| 2021 Mayo | 7 | 7 | 14 |
| 2021 Abril | 16 | 3 | 19 |
| 2021 Marzo | 6 | 6 | 12 |
| 2021 Febrero | 10 | 10 | 20 |
| 2021 Enero | 6 | 11 | 17 |
| 2020 Diciembre | 14 | 8 | 22 |
| 2020 Noviembre | 7 | 5 | 12 |
| 2020 Octubre | 6 | 7 | 13 |
| 2020 Septiembre | 8 | 30 | 38 |
| 2020 Agosto | 14 | 33 | 47 |
| 2020 Julio | 8 | 14 | 22 |
| 2020 Junio | 2 | 4 | 6 |
| 2020 Mayo | 5 | 9 | 14 |
| 2020 Abril | 4 | 3 | 7 |
| 2020 Marzo | 12 | 8 | 20 |
| 2020 Febrero | 11 | 6 | 17 |
| 2020 Enero | 12 | 7 | 19 |
| 2019 Diciembre | 9 | 10 | 19 |
| 2019 Noviembre | 8 | 2 | 10 |
| 2019 Octubre | 1 | 17 | 18 |
| 2019 Septiembre | 8 | 6 | 14 |
| 2019 Agosto | 4 | 8 | 12 |
| 2019 Julio | 16 | 22 | 38 |
| 2019 Junio | 21 | 36 | 57 |
| 2019 Mayo | 48 | 61 | 109 |
| 2019 Abril | 29 | 22 | 51 |
| 2019 Marzo | 5 | 11 | 16 |
| 2019 Febrero | 2 | 22 | 24 |
| 2019 Enero | 2 | 5 | 7 |
| 2018 Diciembre | 2 | 4 | 6 |
| 2018 Noviembre | 2 | 10 | 12 |
| 2018 Octubre | 4 | 2 | 6 |
| 2018 Septiembre | 7 | 5 | 12 |
| 2018 Agosto | 3 | 23 | 26 |
| 2018 Julio | 1 | 5 | 6 |
| 2018 Junio | 2 | 11 | 13 |
| 2018 Mayo | 1 | 11 | 12 |
| 2018 Abril | 4 | 3 | 7 |
| 2018 Marzo | 2 | 5 | 7 |
| 2018 Febrero | 1 | 2 | 3 |
| 2018 Enero | 4 | 3 | 7 |
| 2017 Diciembre | 3 | 2 | 5 |
| 2017 Noviembre | 3 | 4 | 7 |
| 2017 Octubre | 5 | 6 | 11 |
| 2017 Septiembre | 3 | 16 | 19 |
| 2017 Agosto | 3 | 0 | 3 |
| 2017 Julio | 3 | 10 | 13 |
| 2017 Junio | 5 | 1 | 6 |
| 2017 Mayo | 7 | 4 | 11 |
| 2017 Abril | 5 | 1 | 6 |
| 2017 Marzo | 14 | 2 | 16 |
| 2017 Febrero | 10 | 3 | 13 |
| 2017 Enero | 11 | 1 | 12 |
| 2016 Diciembre | 9 | 0 | 9 |
| 2016 Noviembre | 2 | 1 | 3 |
| 2016 Octubre | 9 | 3 | 12 |
| 2016 Septiembre | 9 | 2 | 11 |
| 2016 Agosto | 9 | 2 | 11 |
| 2016 Julio | 5 | 1 | 6 |
| 2016 Junio | 10 | 12 | 22 |
| 2016 Mayo | 8 | 11 | 19 |
| 2016 Abril | 11 | 15 | 26 |
| 2016 Marzo | 12 | 10 | 22 |
| 2016 Febrero | 4 | 10 | 14 |
| 2016 Enero | 2 | 18 | 20 |
| 2015 Diciembre | 5 | 10 | 15 |
| 2015 Noviembre | 16 | 8 | 24 |
| 2015 Octubre | 8 | 9 | 17 |
| 2015 Septiembre | 6 | 10 | 16 |
| 2015 Agosto | 9 | 4 | 13 |
| 2015 Julio | 8 | 3 | 11 |
| 2015 Junio | 4 | 3 | 7 |
| 2015 Mayo | 3 | 3 | 6 |
| 2015 Abril | 6 | 5 | 11 |
| 2015 Marzo | 5 | 1 | 6 |
| 2015 Febrero | 7 | 4 | 11 |
| 2015 Enero | 13 | 5 | 18 |
| 2014 Diciembre | 21 | 5 | 26 |
| 2014 Noviembre | 13 | 2 | 15 |
| 2014 Octubre | 19 | 2 | 21 |
| 2014 Septiembre | 9 | 1 | 10 |
| 2014 Agosto | 8 | 1 | 9 |
| 2014 Julio | 20 | 2 | 22 |
| 2014 Junio | 19 | 1 | 20 |
| 2014 Mayo | 8 | 1 | 9 |
| 2014 Abril | 15 | 2 | 17 |
| 2014 Marzo | 12 | 1 | 13 |
| 2014 Febrero | 11 | 0 | 11 |
| 2014 Enero | 12 | 3 | 15 |
| 2013 Diciembre | 21 | 4 | 25 |
| 2013 Noviembre | 13 | 5 | 18 |
| 2013 Octubre | 8 | 5 | 13 |
| 2013 Septiembre | 13 | 14 | 27 |
| 2013 Agosto | 23 | 7 | 30 |
| 2013 Julio | 10 | 3 | 13 |
| 2008 Diciembre | 293 | 0 | 293 |
Mostrar todo
